focus -WSS

focus

author：Wikipedia 2025-09-29 01:39:20 - browse：8

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Military medical care influenced by rank and race, new study finds

WSS

FAMU bans football players from facility after release of rap video shot in team's locker room

Weekend shootings leave at least 6 dead, 20 others wounded in Chicago

Sophia Smith scores twice for US in in 3

Venture capitalist Bob Kocher on the state of digital health

Where does female orgasm come from? Scientists think they know

Case highlights the risks of experimental stem cell therapy

entertainment

focus

hotspot

Sports medicine is finally prioritizing gender equality

Bird flu: Don't repeat Covid's 'health versus the economy' framing

Trump demands the U.S. pay no more for drugs than other countries … again

FDA approves first blood sugar monitor without finger pricks

Sports medicine is finally prioritizing gender equality

Hundreds of thousands march in Israel. Former security chiefs beg Netanyahu to halt legal overhaul

Dobbs anniversary: the lost opportunity of abortion as health care

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

Malaria cases in Florida and Texas: Here’s what you need to know

Woman found dead after suspected bear encounter near Yellowstone, wildlife officials say

focus

PrEP can help anyone prevent HIV. Why do so few people take it?

Anxious about a speech? A startup wants you to pop a minty cardiac drug

New requirements coming in 2024 for Americans traveling to Europe

Cytokinetics CEO stresses company can launch heart drug on its own

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

Anxious about a speech? A startup wants you to pop a minty cardiac drug

focus

focus

entertainment

Wikipedia